Link to bioRxiv paper:

http://biorxiv.org/cgi/content/short/2020.08.03.232561v1?rss=1

Authors: Lai, T.-h., Ozer, H. G., Gasparini, P., Giovanni, N., Destafano, R., Ravikrishnan, J., Tsai, T.-l., Lapalombella, R., Woyach, J., Puduvalli, V., Blachly, J., Byrd, J. C., Sampath, D.

Abstract:

HDAC1 is a key regulator of gene expression in cancer. We identified a critical role for HDAC1 in establishing the transcriptional dependencies essential for survival in chronic lymphocytic leukemia (CLL) by profiling HDAC1 with BRD4, H3K27Ac superenhancers, H4K9Ac, chromatin accessibility signatures, Pol2 measurements and expression signatures to generate a regulatory chromatin landscape. Superenhancers marked by high levels of acetylation and BRD4 paradoxically also recruited the highest levels of HDAC1. HDAC inhibition poisoned transcription at these loci to selectively disrupt B-cell transcription factors and B-cell receptor signaling. HDAC1 was also recruited genome-wide at promoters without superenhancers to repress expression; HDAC inhibition reverses silencing at these loci, which include key microRNA networks that reciprocally downregulate CLL specific survival and driver genes. Our work provides a compelling rationale for profiling HDAC1 across cancers to characterize its role in driving transcriptional dysregulation that is a hallmark of most cancers and develop epigenetic therapeutic strategies.

Copy rights belong to original authors. Visit the link for more info